Philip Ryan, MD
Endocrinology, Diabetes & Metabolism · Martinsburg, WVNPI 1043396229
Payments from drug & device makers
Across 741 payments — averaging $47.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$11K
- AbbVie$9K
- Esperion Therapeutics, Inc.$4K
- Lilly USA, LLC$3K
- Novo Nordisk$1K
- Boehringer Ingelheim$827
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$20,50058%
- Travel & lodging$1,8655%
- Food & beverage$13,00037%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 33 | $11,399 |
| AbbVie | 118 | $9,439 |
| Esperion Therapeutics, Inc. | 38 | $4,318 |
| Lilly USA, LLC | 134 | $2,658 |
| Novo Nordisk | 75 | $1,248 |
| Boehringer Ingelheim | 48 | $827 |
| Amgen(2 entities) | 28 | $655 |
| Abbott | 46 | $647 |
| Bayer | 34 | $636 |
| Sanofi-aventis U.S. LLC | 32 | $526 |
| Corcept Therapeutics | 21 | $492 |
| Antares Pharma, Inc. | 13 | $319 |
| Dexcom, Inc. | 11 | $312 |
| AstraZeneca(2 entities) | 17 | $280 |
| Xeris Pharmaceuticals, Inc. | 11 | $210 |
| Novartis | 9 | $150 |
| Johnson & Johnson | 12 | $149 |
| Verity Pharmaceuticals Inc. | 5 | $112 |
| Tolmar, Inc. | 6 | $92 |
| Halozyme Inc | 4 | $89 |
| Insulet Corporation | 5 | $84 |
| Astellas Pharma US Inc | 4 | $80 |
| Clarus Therapeutics Inc. | 4 | $77 |
| Pfizer | 4 | $66 |
| Medtronic(2 entities) | 2 | $61 |
| IBSA Pharma Inc. | 4 | $58 |
| Currax Pharmaceuticals LLC | 4 | $55 |
| Lifescan, Inc. | 2 | $50 |
| Alvogen Inc | 2 | $48 |
| Aytu Biopharma, Inc. | 3 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Medicure Pharma Inc. | 1 | $27 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 2 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| BD | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,390 in reported general payments places this provider in the 90th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 224 | $442,472 |
| TrulicityDulaglutide | 125 | $177,458 |
| GlyxambiEmpagliflozin/Linagliptin | 101 | $157,661 |
| OzempicSemaglutide | 86 | $138,662 |
| JardianceEmpagliflozin | 75 | $98,799 |
| PremarinEstrogens, Conjugated | 132 | $60,679 |
| JanuviaSitagliptin Phosphate | 63 | $49,567 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $45,723 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $41,734 |
| TradjentaLinagliptin | 19 | $24,941 |
| NexlizetBempedoic Acid/Ezetimibe | 31 | $23,701 |
| ProliaDenosumab | 13 | $22,954 |
| VascepaIcosapent Ethyl | 22 | $19,591 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $14,436 |
| SynthroidLevothyroxine Sodium | 135 | $13,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,658 | $619,930349 claims |
| Boehringer IngelheimGlyxambi, Jardiance, Tradjenta, Jentadueto | $827 | $292,078209 claims |
| Novo NordiskOzempic | $1,248 | $138,66286 claims |
| PfizerPremarin, Levoxyl | $66 | $62,291165 claims |
| MerckJanuvia | $24 | $49,56763 claims |
| Esperion Therapeutics, Inc.Nexlizet | $4,318 | $23,70131 claims |
| AmgenProlia | $655 | $22,95413 claims |
| AbbVieSynthroid | $9,439 | $13,472135 claims |
| AstraZenecaFarxiga | $280 | $11,11019 claims |
| Antares Pharma, Inc.Xyosted | $319 | $6,73711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Martinsburg
- Zachary KistkaMartinsburg$120K
- Sheila Ramirez RodriguezMartinsburg$5K
- James FieldMartinsburg$930
- Emma Morton-EgglestonMartinsburg$206
- Ayman ElkadryHuntington$767K
- Daniel MaciasHuntington$686K
- Jeremy SouleBridgeport$120K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.